VIM and renal cell carcinoma: For instance, miR-138-5p inhibits metastasis and EMT by targeting vimentin in breast cancer and renal cell carcinoma [27,28], and a novel feedback loop exists between miR-124-3p and the TGF-β pathway driving NSCLC metastasis [29].